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INTRODUCTION
To decide the proper administration of analgesic doses for
the patients suffering from the cancer pain, pain clinicians are
frequently skipping three-step analgesic ladder, as started in
the WHO Guidelines of September 1986 on cancer pain man-
agement (1). A transdermal therapeutic system (TTS) of fen-
tanyl was introduced in Korea in 1995. TTS fentanyl enables
the noninvasive opioid administration in patients with dys-
phasia; patients who cannot tolerate oral therapy due to can-
cer-related side effects or due to side effects of the oral opioid
itself (2). Now just like using the neural blockade or neural
ablation at any steps, for the patients, who consider transder-
mal opioid as the best route to tolerate opioid-related side ef-
fects, transdermal fentanyl is another drug of choice to treat
visceral and neuropathic pain from the cancer. 
The purpose of the study was to investigate: 1) feasibility of
direct conversion from naive and mild opioids to strong opioids
fentanyl patch for the analgesia with concomitant administra-
tion of adjuvant drugs; 2) appropriate application intervals of
TTS fentanyl for the effective analgesia; and 3) factors affecting
patients’ satisfaction and side effects on the clinical trial.
MATERIALS AND METHODS
The study was conducted in Pain Clinics of 2 University
Hospitals in Korea for 29 days from June 2001 to June 2002.
The study group consisted of 37 patients (14 men and 23 wo-
men; age range: 23-81 yr, mean±SD 51.7±12.0 yr) exclud-
ing 7 eliminated patients, with consultation from other depart-
ments due to uncontrolled cancer pain. The underlying prima-
ry tumor location listed in Table 1.
Inclusion criteria were: 1) patients who finished second out-
patient department (OPD) visit and documented case sheets
patients until Day 15; 2) histologically confirmed malignan-
cy; 3) patients aged over 18 yr; 4) ability to communicate effec-
tively with the study personnel regarding the nature of pain
and quality of life of the patient; 5) adequate communication
and cooperation with the family of the patient; 6) informed
consent of the patient; and 7) intractable cancer pain treated
with NSAIDs, mild opioids, and subcutaneous, intravenous,
or intramuscular strong opioid administration intermittent-
ly <3 times/day for the rescue medication.
Exclusion criteria were: 1) patients already continuing med-
ication with strong opioids for pain managements; 2) dying
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Initial Dose Cascade of TTS Fentanyl with Proper Adjuvant
Medications in Cancer Pain
According to the three step-ladder analgesics in patients with cancer pain, adjuvant
drugs are required for pain relief according to the pain character and also to reduce
side effects of opioids. Pain clinicians sometimes want to decide to jump directly
from naive and mild opioid to transdermal therapeutic system (TTS) fentanyl with
less side effects. We investigated the safety, efficacy, and satisfaction of the pa-
tients of TTS fentanyl converting from opioid-naive and mild-opioid with adjuvant
drug medications in related to dose cascade of TTS fentanyl. Both opioid-naive
(n=3) and opioid-using (n=34) patients started with TTS fentanyl in the lowest avail-
able delivery rate (25  g/hr) with rescue medication. A numeric rating scale (NRS,
from 0=no pain to 10=worst pain imaginable), satisfaction of the patients with the
transdermal therapy and side effects were recorded everyday during 29 days. Aver-
age reductions of NRS scores were 1.79 and 2.77, and the mean doses were
35.14 and 44.12  g/hr on the 15th and 29th day, respectively. Reported level of
satisfaction with the transdermal patch and generalized pain management were
‘completely satisfied’ and ‘satisfied’. Frequent side effects were nausea, vomiting,
and constipation. In conclusion, initial application of TTS fentanyl with proper adju-
vant medications is effective, safe, and well tolerated.
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patients or patients with impaired consciousness; 3) a history
of CO2-retention or other pulmonary problems; and 4) hepto-
renal failure (AST, ALT >100 U, BUN >10 mg/dL and Cr.
>2.5 mg/dL).
The patients were hospitalized for the first 3 days of the study
at least, and went through the baseline laboratory examination
and medication for pain during the time. The investigators
then had visited or phoned daily throughout the 29-day trial
to evaluate the efficacy and safety of the TTS fentanyl. For the
initial dose of transdermal fentanyl (Durogesic
�, Janssen, Beerse,
Belgium), the lowest delivery rate of 25 mg/hr was applied
and the same application intervals had to be kept for 3 days
according to the ordinary prescription method. On the first
day of application, analgesics used before were continued until
the initiation of effect of fentanyl patch.
Subcutaneous or intravenous morphine of 5 mg or suppos-
itory morphine of 10 mg was supplied as rescue medication
when sufficient relief from pain was not adequate, because of
either inadequate transdermal fentanyl dose or breakthrough
pain. Through the trial, dose adjustment of fentanyl was deter-
mined by converting the mean daily rescue morphine dose,
when needed on a regular basis over the 3 days preceding a
patch renewal. In addition to the three step-ladder analgesics,
adjuvant drugs including antidepressants, anticonvulsants,
oral anesthetics, corticosteroids, myotonolytics, and neurolep-
tics were given to relieve from pain and to reduce opioid-relat-
ed side effects. Depending on the rescue dose of morphine over
3 times in a day, we decided to increase the dose of fentanyl
patch starting at next changing time.
The application sites were upper torso and upper arm, and
had to be both nonirritated and nonirradiated. Rotation with
each application site would be helpful to reduce skin reaction
and variations in blood levels resulting from alterations in the
skin under the previous patch.
At the beginning of the study, all patients had a physical
examination and routine laboratory control. The investigators
made baseline assessments of pain using a numeric rating scale
(from 0=no pain to 10=worst pain imaginable) and overall
satisfaction with application of fentanyl patch using verbal
rating scale 1-5, with 1) not at all satisfied, 2) not satisfied, 3)
fairly satisfied, 4) satisfied, and 5) completely satisfied. And
the overall reported satisfaction of the patients for the pain con-
trol had used by the same scale as above.
Patients or their family members at home were requested
to write pain diary, which includes pain score, side effects, and
rescue dose every day through the 29-day study. Patients had
visited on the 15th and 29th days routinely. If patients had
experienced some intolerable side effects such as nausea, vom-
iting, constipation, itching, respiratory depression, decreased
mental status, or detachment from the skin due to sweating,
anyone in the family was requested to contact us immediately
and to be instructed by the treating doctors.
Statistical analysis was performed with  2-test and Student’s
t-test, as appropriate. The parametric data described as mean
±SD. Mantel-Haenszel chi-square test was used to evaluate
the change of overall rate of satisfaction of the patients accord-
ing to the TTS fentanyl dose increasing. Repeated measures
ANOVA test was performed to compare daily changes of visual
analogue scale between overall satisfaction and dissatisfaction
group. Correlation analysis was performed to find out signifi-
cant variables to influence the overall rate of satisfaction of the
patients during treatment by using the logistic regression and
the Fisher’s exact test.
RESULTS
Among 44 patients, 7 patients were dropped out during the
study due to intended removal of patch by patients themselves
because of severe vomiting (n=2), hyperhidrosis (n=1), dizzi-
Ovary/Cervix 10 (27)
Gastrointestinal tract 7 (19)
Head and Neck 5 (14)
Kidney/Bladder 4 (11)
Hepatobiliary 3 (8)
Lung 3 (8)
Other 5 (14)
Tumor location No. of patients (%)
Table 1. The underlying primary tumor location of participant
patients
TTS fentanyl    25  g/hr - 37 (100) 24 (65) 18 (53)
50 g/hr - - 11  (30) 8  (24)
75 g/hr - - 2  (5) 6  (18)
100 g/hr - - - 2  (5)
Mean dose ( g/hr) - 25.0 35.1 44.1
Acetaminophen 14 (38) 9 (24) 8 (22) 7 (21)
Acetyl salicylate 1 (3) - 1 (3) 1 (3)
Codeine derivatives 27 (73) 23 (62) 1 (3) -
Opioids* 8 (22) 6 (16) - -
NSAIDs 14 (38) 12 (32) 6 (16) 4 (12)
Tramadol 9 (24) 7 (20) 6 (16) 5 (15)
Antidepressants - 11 (30) 13 (35) 11 (32)
Anticonvulsants - 9 (24) 10 (27) 8 (24)
Minor tranquilizers - 9 (24) 7 (19) 8 (24)
Antiemetics - 8 (22) 6 (16) 5 (15)
Laxatives - 5 (14) 7 (19) 7 (21)
Muscle relaxants - 4 (11) 3 (8) 3 (9)
Antidiarrheals - 1 (3) - -
Steroids - - 4 (11) 2 (6)
During 2 wks
prior to study
(n=37)
Study days
1st day 
(n=37)
15th day 
(n=37)
29th day
(n=34)
Table 2. Medications used before and during the study
Data are numbers (%) of patients, TTS fentanyl=transdermal thera-
peutic system fentanyl.
*4 morphine (3 subcutaneous and 1 intravenous), 3 hycodone (oral),
and 2 meperidine (intramuswlas). Four patients were prescribed two
kinds of opioids simultaneously.ness (n=1), severe abdominal pain (n=1), concomitant occur-
ring paraplegia, urinary incontinence, and aphasia due to mul-
tiple cancer metastasis (n=1), and death from pulmonary em-
bolism (n=1). After second OPD visit, 3 patients could not
finish final report due to death (one from electrolyte imbalance
on the 18th day and the other from severe dyspnea related
pulmonary edema and acute renal failure on the 20th day),
and self removal due to severe vomiting on the 25th day.
TTS fentanyl and various adjuvant medication administered
during the study period and medications administered within
2 weeks before the study were presented on the Table 2. Mor-
phine, codeine derivatives, hycodone, and meperidine were
prescribed for the breakthrough pain as needed before and dur-
ing the study period. Four patients were prescribed two kinds
of opioids simultaneously. Various adjuvant drugs were noted
on the first day of the study.
The numeric rating scale (NRS) pain scores of satisfaction
group who were completely satisfied or satisfied with appli-
cation of fentanyl patch were significantly lower than that of
dissatisfactory group who were not at all satisfied or not sat-
isfied. From the 18th day of the study, the two groups showed
statistically significant difference on the pain scores (p=0.0024,
Fig. 1).
Eighty-five and 88% of patients were satisfied with patch
form opioid therapy and overall pain control with TTS fenta-
nyl, respectively. The dosage of TTS fentanyl had influenced
on the rate of satisfaction of the patients (p=0.003) (Table 3).
The univariate logistic regression analysis showed that pain,
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Satisfaction with patch form opioid - 1 (3) 4 (12) 17 (50) 12 (35)
therapy
Overall satisfaction with pain control - 1 (3) 3 (12) 16 (47) 14 (41)
Satisfaction according to the
dose of TTS fentanyl
�
25 g/hr - - - 6  (18) 12
50  g/hr - - 1 (3) 5 (15) 2 (6)
75  g/hr - 1 (3) 1 (3) 4 (12) -
100  g/hr - - 1 (3) 1 (3) -
Table 3. Assessment of overall satisfaction during the study
Numeric rating scale*
12 3 4 5
Data are numbers (%) of patients.
TTS fentanyl = transdermal therapeutic system fentanyl.
*1=not at all satisfied; 2=not satisfied; 3=fairly satisfied; 4=satisfied;
5=completely satisfied. 
� p-value=0.003 from the Mantel-Haenszel chi-
square test.
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Fig. 1. Comparison of numeric rating scale between overall satisfac-
tion and dissatisfaction group with application of TTS fentanyl.
TTS=transdermal therapeutic system.
Statistical analysis was done with Pooled or Satterhwaite method.
*p <0.05. 
� p <0.01. 
� Completely satisfied to satisfied and 
�fairly satisfied
to not at all satisfied with overall pain management with TTS fentanyl,
respectively.
Male/Female 11/19 2/2 1.73 (0.21-14.05) NS NS
Pain (0-4/5-10) 25/5 1/3 15.00* (1.28-175.30) NS NS
TTS fentanyl dosage
(25-50/75-100 g/hr) 25/5 1/3 15.00* (1.28-175.30) NS NS
Satisfaction to patch form opioid therapy 28/2 1/3 42.00
� (2.88-621.29) 42.00
� (2.88-621.29)
Rescue medication
‖ (Y/N) 5/25 3/1 15.00* (1.28-175.30) NS NS
Defecation
No./wk (≥3/<3) 29/1 4/0 - - - -
Hardness
(Diarrhea-normal/Constipation) 19/11 2/2 1.73 (0.21-14.05) - -
Difficulty on defecation (Y/N) 13/17 3/1 3.92 (0.37-42.19) - -
Use of laxatives
¶ (Y/N) 10/20 2/2 2.00 (0.244-16.362) - -
Skin reaction** (Y/N) 2/28 0/4 - - - -
Overall Satisfaction
Satisfied
�(n=30)
Variables
Unsatisfied
� (n=4) OR 95% CI OR 95% CI
Univariate LR Multivariate LR
Table 4. Potential predictors of overall satisfaction to the TTS fentanyl by logistic regression (LR) analysis
Data are number of patients. p values and odds ratios (OR) are given to the variables that were experienced by ≥5% of either group. These values
cannot be directly computed from the information provided. 95% CI=95% confidence interval, NS=not significant, Y=yes, N=no.
*p<0.05. 
� p<0.01. 
� Completely satisfied and satisfied and 
�fairly satisfied to not at all satisfied with overall pain management with TTS fentanyl.
‖Mor-
phine (intravenous, rectal suppository, oral, subcutaneous). 
¶MgO, glycerine enema, and bisacodyl, etc. **Erythema, edema, and itching.
�
� �736 S.W. Baik, K.H. Kim, Y.C. Kim, et al.
dosage of TTS fentanyl, satisfaction to patch form opioid ther-
apy, and rescue medication were significantly related to the
overall satisfaction with TTS fentanyl therapy. However, satis-
faction with patch form opioid therapy only showed closely
related on the multivariate regression analysis (Table 4).
During the study, frequent complaints associated with appli-
cation of fentanyl patch were nausea (n=14), vomiting (n=11)
and constipation (n=6). And the other side effects were itching
on the application sites (n=2), abdominal pain (n=2), loss of
appetite, urinary retention (n=1), dizziness (n=2), sleepiness
(n=2), general fatigue (n=1), and decreased consciousness (n=
1). Among the side effects, factors affecting to the satisfac-
tion of the patients were nausea, vomiting, and constipa-
tion. Such side effects did not show significant correlation with
the overall satisfaction with TTS fentanyl therapy.
DISCUSSION
There are three major pharmacokinetic features of transder-
mal fentanyl system. The first is a lag period after the first dose
of fentanyl before blood concentrations approach therapeutic
levels. The actual minimal effective concentration may change
depending on the intensity of the pain, the duration of pain,
and the extent of previous opioid therapy. This lag period can
vary from 1 hr to longer than 30 hr, with a mean value of about
13 hr (3). Therefore bridging or supplemental immediate-
release analgesia must be administered for first 13 hr, depend-
ing on the amount and efficacy of the current analgesic regi-
men. A similar situation is likely to arise, if the transdermal
fentanyl dose is increased because of inadequate analgesia. The
abstinence/withdrawal syndrome may occur in the presence
or absence of adequate analgesia. We used the same previous
analgesic regimen on the first application of patch for 1 day
except some changes of adjuvant medications. Patients had
usually received the adequate analgesia around 12 to 24 hr
with feasibility of direct conversion from na1ve and mild opi-
oids to strong opioids fentanyl patch for the analgesia with
concomitant administration of adjuvant drugs, if needed. If
possible, it is more reasonable to apply after dinner to consid-
er this lag period. For the initial dose titration, these options
are recommended: 1) patient-controlled analgesia with fentanyl
to establish an hourly fentanyl demand rate for effective anal-
gesia (4); 2) starting with the lowest possible transdermal fen-
tanyl dose (25  g/hr) and titration according to the response
of the patient (5); or 3) using conversion tables that suggest
a transdermal fentanyl dose taking the current analgesic reg-
imen (in morphine equivalents) into consideration (6, 7). Acc-
ording to equianalgesic dose of opioid agonist analgesics, co-
deine 60 mg/day is similar to fentanyl patch 5  g/hr. There-
fore, if we use codeine 300 mg/day, the effect is the equianal-
gesic dose of fentanyl patch 25  g/hr respectively.
Second, blood concentrations continue to rise and approach
steady by the second dose, or possibly earlier with a 3-day dos-
ing interval (4). In our study, we could find some differences
of NRS scores among the first, second, and third days of appli-
cation of patch. The mean NRS score of the second day (3.49
±0.35) was significantly lower than that of the first day (3.78
±0.71, p=0.0005), however, not significantly different from
that of the third day (3.51±0.40, p=0.0967). So we have to
consider the appropriate application intervals of TTS fentanyl
for the effective analgesia with some patients. Steady-state
blood fentanyl concentrations achieved with a given dose can
vary among patients by factors such as increased skin hydra-
tion, skin damage by disease, chemicals and sun exposure, in-
creased activity of sweat glands, increased perfusion during
exercise, and elevated cutaneous temperature (3).
Third, once the systems are removed, the blood fentanyl con-
centration does not immediately fall at a rate predicted from
intravenous fentanyl pharmacokinetics (3, 5). Thus both
analgesia and any side effects that may be present will decline
gradually after patch removal.
The delay in establishing effective blood fentanyl concentra-
tions occurs because of the time taken to create a cutaneous
depot of fentanyl in the skin covered by the system. Therefore,
the system release fentanyl at a constant rate for up to 3 days.
When the system is removed, a depot of fentanyl remains
in the stratum corneum that was covered by the patch about
10% of the original dose, and absorption continues from
this site thereby maintaining blood fentanyl concentrations.
The dose has varied by increasing or decreasing the number
and/or size of the applied systems from the four available sizes,
and there is dose proportionality with blood fentanyl concent-
rations according to linear pharmacokinetics (4). If we are una-
ble to get the dose of fentanyl patch, 50, 75, and 100  g/hr and
have to use the fentanyl patch with combination of 25  g/hr
only, it can be administrated with over- or under-treatment.
Age seems to have an influence on transdermal fentanyl
pharmacokinetics, specifically in older patients. Elderly patients
usually required early patch removal owing to adverse effects,
compared with younger patients. In contrast, the pharmaco-
kinetics of transdermal fentanyl in children with cancer pain
appears to be similar, but perhaps less variable, than in adults
(8). In our study patients, aged from 25 to 81 yr old, age did
not seem to have less influence on application of fentanyl phar-
macokinetics.
The problem of the adherence or dehiscence of TTS fentanyl
in patients with excessive sweating, in whom there is a possible
reduction in effective surface area for absorption because drop-
lets of fluid form under the patch (9). Among the 7 dropouts,
one patient could not attach the patch because of excessive
sweating.
All of the studies about the rate of satisfaction of the patients
with TTS fentanyl, compared with slow-release morphine
(SRM) formulations, indicated significantly greater satisfaction
and willingness to continue the therapy (5, 9, 10). And a
marked sex difference in satisfaction was shown in one study
in which male but not female patients, reported a preference
. .for TTS fentanyl (10).
We, however, had studied about satisfying factors with fen-
tanyl patch application itself and the reported satisfaction by
the patients with dose escalation of fentanyl. Application of
fentanyl patch to the patients suffering from cancer pain was
noninvasive and easy to learn to apply, to give them relatively
long-term analgesia. So, most of the patients preferred patch
application to other method of drug delivery systems, includ-
ing intravenous and epidural analgesia. And 23 patients among
the 44 participants, including all dropouts suffered from the
opioid-related side effects; nausea (n=14), vomiting (n=11),
constipation (n=6) and so forth. These three side effects were
major complaints and became major unsatisfied factors among
the participants. In some other ways, we can presume the symp-
toms to be cancer-related problems. The group who needed
lower dose of fentanyl, however, seemed to have higher rate
of satisfaction for the pain management than the group who
required higher dose of fentanyl. Therefore, the less opioids
can give them the more satisfaction without side effects. The
best way to reduce the dose of opioids is to find the character-
istics and origins of pain. We tried to administer proper adju-
vant medication as possible (Table 2). Patients with nausea
and vomiting were treated with metoclopramide, ondansetron,
scopolamine, and steroids. And patients with constipation
were treated with MgO, senna, lactulose, bisacodyl, and glyc-
erin enema.
Most patients with advanced cancer develop diverse symp-
toms that can limit the efficacy of pain treatment and under-
mine their quality of life. According to Meuser et al. (11), con-
trollable symptoms were anorexia, impaired activity, confusion,
change of mood, insomnia, constipation, dyspepsia, dyspnea,
coughing, dysphasia, and urinary symptoms. But during the
combination treatment with opioid and adjuvant drugs, seda-
tion, other neuropsychiatric symptoms and dry mouth were
significantly increased. Coma, vertigo, diarrhea, nausea, vom-
iting, intestinal obstruction, erythema, pruritus, and sweating,
however, remained unchanged. The symptoms as being most
frequently caused by the analgesic regimen were only consti-
pation, erythema, and dry mouth. Nevertheless, general, neu-
ropsychiatric, and gastrointestinal symptoms occurred during
a major part of treatment time, and proper relief from pain
was inadequate in 14% of patients. Cancer pain management
has to be embedded in a frame of palliative care, taking all the
possibilities of symptom management into consideration.
We conclude that initial application of TTS fentanyl com-
bined with proper adjuvant medication is effective, safe, and
well tolerated by most patients with cancer pain. And to man-
age nausea, vomiting and constipation induced by TTS fen-
tanyl will increase rate of the satisfaction of the patients during
initial dose cascade of fentanyl. With some patients, we have
to consider the appropriate application intervals of TTS fen-
tanyl for the effective analgesia.
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